专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

121. 发明申请

US20130195919A1 INDUCED DENDRITIC CELL COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译：诱导的细胞组成及其用途
公开(公告)号：US20130195919A1
公开(公告)日：2013-08-01
申请号：US13582897
申请日：2011-03-07
申请人： Ulrich Von Andrian , Roberto Maldonado , Fulvia Vascotto
发明人： Ulrich Von Andrian , Roberto Maldonado , Fulvia Vascotto
IPC分类号： C12N5/0784 , G01N33/50 , A61K35/14
CPC分类号： C12N5/0639 , A61K35/15 , A61K2035/122 , A61K2035/124 , A61K2039/5154 , C12N5/064 , C12N2500/30 , C12N2500/40 , C12N2501/04 , C12N2501/052 , C12N2501/15 , C12N2501/22 , C12N2501/23 , C12N2501/26 , C12N2501/70 , G01N33/5079
摘要： The invention provides, for example, compositions comprising induced tolerogenic dendritic cells which are capable of suppressing an antigen specific T cell-mediated immune response, and to methods of making and using the same. The invention also provides compositions comprising induced immunogenic dendritic cells and methods of making and using them.
摘要翻译：本发明提供了例如包含能够抑制抗原特异性T细胞介导的免疫应答的诱导的耐受性树突状细胞的组合物，以及制备和使用它们的方法。本发明还提供包含诱导的免疫原性树突状细胞的组合物及其制备和使用方法。

122. 发明申请

US20130156778A1 DENDRITIC CELL INHIBITORY PROTEINS FROM TICKS 有权
标题翻译：来自TICKS的致敏细胞抑制蛋白
公开(公告)号：US20130156778A1
公开(公告)日：2013-06-20
申请号：US13636469
申请日：2011-03-23
申请人： Jonathan M. Austyn , Guido Paesen , Stephen Preston , Patricia Nuttal
发明人： Jonathan M. Austyn , Guido Paesen , Stephen Preston , Patricia Nuttal
IPC分类号： C07K14/435 , C12N5/0784 , A61K45/06 , A61K35/14 , A61K39/395 , C07K16/18 , A61K39/00
CPC分类号： C07K14/43527 , A61K35/15 , A61K38/1767 , A61K39/0003 , A61K39/3955 , A61K45/06 , C07K14/4702 , C07K16/18 , C12N5/0639 , Y02A50/401 , A61K2300/00
摘要： The present invention provides a dendritic cell modulatory protein which modulates, and preferably inhibits, the differentiation and/or maturation of mammalian dendritic cells. The invention also provides proteins comprising conserved motifs found in such proteins as well as pharmaceutical compositions comprising the dendritic cell modulatory protein and homologues and active fragments thereof, antibodies thereto and methods of treatment which utilise such proteins, homologues, fragments and antibodies.
摘要翻译：本发明提供了调节并优选抑制哺乳动物树突细胞的分化和/或成熟的树突状细胞调节蛋白。本发明还提供了包含在这些蛋白质中发现的保守基序的蛋白质以及包含树突状细胞调节蛋白及其同系物及其活性片段，其抗体的药物组合物，以及利用这些蛋白质，同系物，片段和抗体的治疗方法。

123. 发明申请

US20130058974A1 ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES 审中-公开
标题翻译：抗原特异性诱导的嗜酸性细胞减少CYTOTOXIC T淋巴细胞反应
公开(公告)号：US20130058974A1
公开(公告)日：2013-03-07
申请号：US13457636
申请日：2012-04-27
申请人： Roberto A. Maldonado , Takashi Kei Kishimoto
发明人： Roberto A. Maldonado , Takashi Kei Kishimoto
IPC分类号： A61K35/12 , A61K39/00 , A61P37/08 , A61P29/00 , A61P37/00 , A61P37/06 , C12N5/0784 , A61K39/35
CPC分类号： A61K38/1816 , A61K38/19 , A61K38/20 , A61K38/21 , A61K38/212 , A61K38/44 , A61K38/47 , A61K38/57 , A61K39/0008 , A61K2035/122 , A61K2039/5154 , A61K2039/577 , C12Y302/01022 , C12Y302/01045
摘要： Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing CD8+ T cell immune responses, as well as related compositions and methods.
摘要翻译：公开了用于降低CD8 + T细胞免疫应答的抗原特异性诱导的耐受性树突状细胞（itDC），以及相关组合物和方法。

124. 发明申请

US20130058901A1 TRANSPLANTABLE GRAFT-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE 审中-公开
标题翻译：可迁移的特异性诱导的嗜酸性细胞和使用方法
公开(公告)号：US20130058901A1
公开(公告)日：2013-03-07
申请号：US13457650
申请日：2012-04-27
申请人： Roberto A. Maldonado , Takashi Kei Kishimoto
发明人： Roberto A. Maldonado , Takashi Kei Kishimoto
IPC分类号： A61K35/12 , G01N33/577 , C12N5/0784
CPC分类号： A61K38/1816 , A61K38/19 , A61K38/20 , A61K38/21 , A61K38/212 , A61K38/44 , A61K38/47 , A61K38/57 , A61K39/0008 , A61K2035/122 , A61K2039/5154 , A61K2039/577 , C12Y302/01022 , C12Y302/01045
摘要： Disclosed are transplantable graft-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods.
摘要翻译：公开了可移植的移植物特异性诱导的耐受性树突状细胞（itDC）以及相关组合物和方法。

125. 发明申请

US20130052211A1 VACCINES WITH ONCOFETAL ANTIGEN/ILRP-LOADED AUTOLOGOUS DENDRITIC CELLS AND USES THEREOF 审中-公开
标题翻译：具有ONCOFETAL抗原/ ILRP载体的自体细胞细胞的疫苗及其用途
公开(公告)号：US20130052211A1
公开(公告)日：2013-02-28
申请号：US13383103
申请日：2010-07-09
申请人： Adel L. Barsoum , Suzanne Rohrer , Cindy C. Segers , Kurt M. Coggin
发明人： Adel L. Barsoum , James W. Rohrer , Joseph H. Coggin, JR.
IPC分类号： A61K39/00 , G01N33/569 , C12N5/0784 , A61P37/04 , A61P35/00
CPC分类号： A61K39/0011 , A61K35/26 , A61K2039/5154 , C12N5/0639 , C12N2501/02 , C12N2501/22 , C12N2501/23 , C12N2501/25
摘要： Disclosed are compositions containing isolated monocyte-derived mature dendritic cells loaded with OFA/iLRP, or a fragment thereof that selectively stimulates T cytotoxic lymphocytes, and a carrier, vaccine compositions containing effective dosage amounts of the dendritic cells, methods of making the vaccines, and methods of cancer treatment or therapy that entail administration of the vaccines to cancer patients.
摘要翻译：公开了含有分离的单核细胞衍生的成熟树突状细胞的装配有选择性刺激T细胞毒性淋巴细胞的OFA / iLRP或其片段的载体，含有有效剂量的树突细胞的载体，疫苗组合物，制备疫苗的方法和癌症治疗或治疗方法需要将疫苗给予癌症患者。

126. 发明申请

US20130034574A1 MODIFIED MELK PEPTIDES AND VACCINES CONTAINING THE SAME 有权
标题翻译：改良的梅毒肽和含有其的疫苗
公开(公告)号：US20130034574A1
公开(公告)日：2013-02-07
申请号：US13574774
申请日：2011-01-24
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K39/00 , C12N15/12 , C12N5/10 , C12N15/85 , C12N5/0784 , C12N5/0783 , C07K7/06 , A61P35/00
CPC分类号： C12Y207/11025 , A61K39/0011 , A61K39/39 , C12N9/1205
摘要： Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances and compositions of this invention find particular utility in the treatment of cancers, tumors, and endometriosis.
摘要翻译：由修饰的MELK表位肽或其免疫活性片段的氨基酸序列组成的分离肽，其结合HLA抗原并且具有比野生型MELK表位肽更高的细胞毒性T淋巴细胞（CTL）诱导性，因此适用于本文描述了癌症免疫治疗或子宫内膜异位症免疫治疗的背景，更特别的是癌症或子宫内膜异位症疫苗。本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。进一步提供了编码这些上述肽中的任何一种的核酸以及包含上述肽或核酸中任何一种的药物物质和组合物。本发明的肽，核酸，药物和组合物在癌症，肿瘤和子宫内膜异位症的治疗中具有特别的用途。

127. 发明申请

US20130028915A1 DENDRITIC CELL (DC)-VACCINE THERAPY FOR PANCREATIC CANCER 审中-公开
标题翻译： DENDRITIC CELL（DC）-VACCINE THERAPY FOR PANCREATIC CANCER
公开(公告)号：US20130028915A1
公开(公告)日：2013-01-31
申请号：US13560534
申请日：2012-07-27
申请人： Anna Karolina Palucka , Jacques F. Banchereau , Hideki Ueno
发明人： Anna Karolina Palucka , Jacques F. Banchereau , Hideki Ueno
IPC分类号： A61K39/00 , A61P35/00 , C12N5/0784 , A61K39/395
CPC分类号： A61K45/06 , A61K39/0011 , A61K2039/5154 , C12N5/0639 , A61K2300/00
摘要： Compositions and methods for eliciting therapeutic immunity and improving clinical outcomes in patients with pancreatic cancer are disclosed herein. The present invention describes a dendritic cell (DC)-vaccine comprising DCs pulsed with peptides derived from pancreatic cancer antigens for the therapy against pancreatic cancer. The vaccine described herein is safe, and leads to expansion of cancer specific T cells in patients with pancreatic cancer.
摘要翻译：本文公开了用于引发治疗免疫和改善胰腺癌患者的临床结果的组合物和方法。本发明描述了一种树突状细胞（DC） - 疫苗，其包含用胰蛋白酶治疗胰腺癌抗原衍生的肽脉冲的DCs。本文所述的疫苗是安全的，并且导致胰腺癌患者中癌症特异性T细胞的扩增。

128. 发明授权

US08236320B2 Compositions and methods for using CA9 protein to stimulate an immune response 有权
标题翻译：使用CA9蛋白刺激免疫应答的组合物和方法
公开(公告)号：US08236320B2
公开(公告)日：2012-08-07
申请号：US12263756
申请日：2008-11-03
申请人： Hyung L. Kim , Yanping Wang , Xiang-Yang Wang , John R. Subjeck
发明人： Hyung L. Kim , Yanping Wang , Xiang-Yang Wang , John R. Subjeck
IPC分类号： A61K39/00 , A61K39/385 , C12N5/0784
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/6031 , A61K2039/6043 , A61K2039/622
摘要： Provided are methods for stimulating an immune response to an antigen by administering a composition to an individual in an amount effective to stimulate an immune response to the antigen. The stimulated immune response to the antigen is greater than the immune response stimulated by the antigen in the absence of CA9 protein. The compositions provided contain a complex that includes an antigen and an isolated CA9 protein.
摘要翻译：提供了通过以有效刺激对抗原的免疫应答的量向个体施用组合物来刺激对抗原的免疫应答的方法。对抗原的刺激免疫应答大于在不存在CA9蛋白时由抗原刺激的免疫应答。提供的组合物含有包含抗原和分离的CA9蛋白的复合物。

129. 发明申请

US20120142106A1 Method Of Forming Dendritic Cells From Embryonic Stem Cells 有权
标题翻译：从胚胎干细胞形成树突状细胞的方法
公开(公告)号：US20120142106A1
公开(公告)日：2012-06-07
申请号：US13364074
申请日：2012-02-01
申请人： Igor I. Slukvin , James A. Thomson , Maksym A. Vodyanyk , Maryna E. Gumenyuk
发明人： Igor I. Slukvin , James A. Thomson , Maksym A. Vodyanyk , Maryna E. Gumenyuk
IPC分类号： C12N5/0784 , C12N15/07
CPC分类号： C12N5/0639 , C12N5/064 , C12N2506/02
摘要： This invention relates to the culture of dendritic cells from human embryonic stem (ES) cells. Human ES cells are first cultured into hematopoietic cells by co-culture with stromal cells. The cells now differentiated into the hematopoietic lineage are then cultured with GM-CSF to create a culture of myeloid precursor cells. Culture of the myeloid precursor cells with the cytokines GM-CSF and IL-4 causes functional dendritic cells to be generated. The dendritic cells have a unique phenotype, as indicated by their combination of cell surface markers.
摘要翻译：本发明涉及来自人胚胎干（ES）细胞的树突状细胞的培养。首先通过与基质细胞共培养将人类ES细胞培养成造血细胞。然后将分化成造血谱系的细胞与GM-CSF一起培养以产生骨髓前体细胞的培养物。用细胞因子GM-CSF和IL-4培养骨髓前体细胞会导致产生功能性树突状细胞。树突细胞具有独特的表型，如细胞表面标志物的组合所示。

130. 发明申请

US20120064122A1 TREATMENT OF AUTOIMMUNE INFLAMMATION USING MIR-155 审中-公开
标题翻译：使用MIR-155治疗自身免疫炎症
公开(公告)号：US20120064122A1
公开(公告)日：2012-03-15
申请号：US13230695
申请日：2011-09-12
申请人： David Baltimore , Ryan M. O'Connell , Daniel Kahn
发明人： David Baltimore , Ryan M. O'Connell , Daniel Kahn
IPC分类号： A61K31/7088 , A61P37/04 , A61P31/00 , A61P31/04 , A61P31/12 , C12N5/0784 , A61P25/00 , A61P19/02 , A61P1/00 , A61P17/06 , C12N5/0783 , A61P29/00 , A61P37/00
CPC分类号： A61K31/7088 , C12N15/113 , C12N2310/113
摘要： The present disclosure relates to the finding that microRNA-155 plays a role in the development and activity of CD4+ T cells. CD4+ T cell development and function, particularly TH17 and TH1 T cell development, can be modulated by delivery of microRNA-155 (miR-155) or antisense miR-155 to target CD4+ cells or precursor cells. In some embodiments, antisense miR-155 is used to reduce tissue specific autoimmune inflalmmation and to treat autoimmune disease. In addition, miR155 and antisense miR-155 can be used to modulate expression of cytokines from dendritic cells.
摘要翻译：本公开涉及microRNA-155在CD4 + T细胞的发育和活性中起作用的发现。可通过将microRNA-155（miR-155）或反义miR-155递送至靶向CD4 +细胞或前体细胞来调节CD4 + T细胞发育和功能，特别是TH17和TH1T细胞发育。在一些实施方案中，反义miR-155用于减少组织特异性自身免疫炎症并治疗自身免疫性疾病。此外，miR155和反义miR-155可用于调节来自树突状细胞的细胞因子的表达。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式